"Absci's newest partnership with AstraZeneca is further validation of our first-of-its-kind zero-shot generative AI model designed to create new and improved antibody therapeutics, including for previously untreatable diseases," Absci CEO Sean McClain told The Register in a statement.
Joshua Meier, Absci's chief AI officer, previously told The Register that there are more possible antibody variants that can be simulated than there are atoms in the universe.
[
add
]
[
|
|
...
]